Glen Eagle Advisors’s Anavex Life Sciences AVXL Stock Holding History

Glen Eagle Advisors’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-300	Closed	-$5.38K	–	944
2021 Q3	$5.38K	Hold	300	–	–	﹤0.01%	809
2021 Q2	$6.86K	Hold	300	–	–	﹤0.01%	764
2021 Q1	$4.49K	Hold	300	–	–	﹤0.01%	785
2020 Q4	$1.62K	Hold	300	–	–	﹤0.01%	868
2020 Q3	$1.36K	Hold	300	–	–	﹤0.01%	824
2020 Q2	$1.48K	Hold	300	–	–	﹤0.01%	782
2020 Q1	$945	Hold	300	–	–	﹤0.01%	754
2019 Q4	$777	Hold	300	–	–	﹤0.01%	844
2019 Q3	$948	Hold	300	–	–	﹤0.01%	756
2019 Q2	$1.01K	Hold	300	–	–	﹤0.01%	734
2019 Q1	$915	Buy	+300	New	+$717	﹤0.01%	700

Other funds holding AVXL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Glen Eagle Advisors's AVXL Position: Q4 2021 in Review

Glen Eagle Advisors sold out of Anavex Life Sciences (AVXL) in Q4 2021, closing a stake of 300 shares — an estimated $5.38K sold.

Glen Eagle Advisors first reported a position in AVXL in Q1 2019 and held it in 11 quarters. The position peaked at $6.86K in Q2 2021. 149 funds tracked by Wall St. Rank hold AVXL as of Q4 2021.

Glen Eagle Advisors reported no remaining Anavex Life Sciences position as of Q4 2021 after selling out during the quarter.
Glen Eagle Advisors sold 300 Anavex Life Sciences shares in Q4 2021, an estimated $5.38K.
Glen Eagle Advisors first reported a position in Anavex Life Sciences in Q1 2019 and held it in 11 quarters.
Glen Eagle Advisors's Anavex Life Sciences position peaked at $6.86K in Q2 2021.
149 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q4 2021.

Based on Glen Eagle Advisors's 13F filing for Q4 2021, filed 13 Aug 2024.